Drug Discovery & Pharmaceuticals

RSS

Researchers present a new strategy for self-adjuvanting vaccine development

This new article publication from Acta Pharmaceutica Sinica B, discusses a fully synthetic Tn-based three-component cancer vaccine using covalently linked TLR4 ligand MPLA and iNKT cell agonist KRN-7000 as built-in adjuvant effectively protects mice from tumor development.

23 Dec 2022

Research serves as a platform to identify therapeutic drugs for schizophrenia

Inflammation and overactivation of the immune system in the brain can cause loss of synapses and the death of neurons, leading to neurodegenerative and psychiatric diseases.

22 Dec 2022

MGI’s DNBSEQ-T7* facilitates ultra-deep sequencing of high-complexity metagenomic samples

Thanks to high-throughput sequencing technologies, shotgun metagenomic methods were made possible and had effectively transformed microbiology. Today, advances in both short- and long-read technologies are overcoming many of the previous challenges affecting metagenomic profiling, especially of highly complex samples and environment.

From MGI 20 Dec 2022

Newly designed antibiotic effective against multidrug-resistant bacteria

Researchers have designed and synthesized analogs of a new antibiotic that is effective against multidrug-resistant bacteria, opening a new front in the fight against these infections.

20 Dec 2022

Scientists suggest vibrational spectroscopy and nuclear magnetic resonance to evaluate drug concentrations

Scientists at Baltic Federal University have suggested evaluating concentration and chemical composition of drugs by means of vibrational spectroscopy and nuclear magnetic resonance instead of conventional complex approaches.

20 Dec 2022

Decoding nucleic acid-based drugs and vaccines through SEC-SLS analysis

In this interview, Malvern Panalytical’s Product Technical Specialist, Stefan Cairns, discusses how SEC-SLS can be used to understand MRNA vector composition by referencing his latest publication.

From Malvern Panalytical 19 Dec 2022

CN Bio appoints Dr Paul Brooks as Chief Executive Officer

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the appointment of Dr Paul Brooks, formerly the Company’s Chief Business Officer, to the position of CEO with immediate effect. Former CEO, Dr David Hughes, will continue to work with the company in a consultative role within the Company’s Scientific Advisory Board.

From CN-Bio 19 Dec 2022

Mucosal DNA vaccine provides protection against lethal SARS-CoV-2 in mice

Less known to the general public, mucosal vaccination via the mucus membranes could provide robust protection against SARS-CoV-2 infections.

16 Dec 2022

Natural substances show great therapeutic potential to inhibit influenza viruses

Fever, cough, sore throat, and general malaise - the cold season is here, and not only corona but also influenza viruses are spreading again at a rapid pace.

16 Dec 2022

Radical project aims to develop a new method for commercial production of anti-microbial peptides

THE COVID pandemic has revealed just how delicate our public health is in terms of overcoming infectious diseases and antimicrobial resistance.

15 Dec 2022

Study provides new insights for the future development of oral insulin pill

WEHI researchers in Melbourne have answered a 100-year-old question in diabetes research: can a molecule different to insulin have the same effect? The findings provide important insights for the future development of an oral insulin pill.

12 Dec 2022

Structural studies pave the way for cancer drugs that could target only mutated versions

To design drugs that stall the growth of aggressive cancers, it helps to know the structures of the proteins that are revving the cancers' engines.

9 Dec 2022

Researchers design novel compounds with potential as drug treatments for COVID-19

The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has been devastating the entire world. While the vaccination program is advancing, drug treatments for COVID-19 are still highly important for those who become infected.

9 Dec 2022

Discovery of cellular uptake pathway for larger molecules can be harnessed to create new drugs

A fundamental challenge in drug development is the balance between optimizing a drug's lock-and-key fit with its target and the drug's ability to make its way across the cellular membrane and access that target.

8 Dec 2022

Discovery of ’raspberry-shaped’ nanoparticle offers a way to enhance the effectiveness of existing drugs

A newly discovered technique, reported in the journal Nanoscale, offers a low-cost way to enhance the effectiveness of existing drugs.

7 Dec 2022

Pre-Plated Assay Solutions That Can Help Accelerate Biotech

In this interview, we speak with University of Warwick spin-out Cryologyx about their innovative new technology that hopes to revolutionize cell-based assays for researchers across life sciences and drug discovery.

From Cryologyx Ltd 6 Dec 2022

Researchers develop potent yet low-inflammatory mRNA cancer vaccine vectors

Lipid nanoparticle (LNP)-based messenger ribonucleic acid (mRNA) vaccines have recently emerged as a promising strategy for the prevention and treatment of cancers, as well as infectious diseases.

4 Dec 2022

Scaling up the production of customized immune cells for drug development and testing

To prevent testing on animals and create even more precise ways of testing therapeutics, the pharmaceutical industry is increasingly turning to human immune cells.

1 Dec 2022

Integrated approach addresses some of the biggest challenges in natural products drug discovery

Many successful drugs have their origins in natural sources such as plants, fungi, and bacteria, but screening natural products to identify potential drugs remains a difficult undertaking.